{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:28:54Z","timestamp":1707524934692},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,5]]},"DOI":"10.7759\/cureus.34648","type":"journal-article","created":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T18:23:57Z","timestamp":1675621437000},"source":"Crossref","is-referenced-by-count":0,"title":["Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Ahmad M","family":"Rabih","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Niaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishwarya","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Uprety","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Calero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Resah B","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narges","family":"Joshaghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Badla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raman","family":"Goit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia E","family":"Saddik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah N","family":"Dawood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071510","article-title":"Inhibitors of protein convertase subtilisin\/kexin 9 (PCSK9) and acute coronary syndrome (ACS): the state-of-the-art","volume":"10","author":"Iannuzzo G","year":"2021","unstructured":"Iannuzzo G, Gentile M, Bresciani A, et al.. Inhibitors of protein convertase subtilisin\/kexin 9 (PCSK9) and acute coronary syndrome (ACS): the state-of-the-art. J Clin Med. 2021, 10:1510. 10.3390\/jcm10071510","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.09.039","article-title":"Initiating PCSK9 inhibition in hospital for ACS: we can, but does that mean we should?","volume":"74","author":"Schwartz GG","year":"2019","unstructured":"Schwartz GG, Chaitman BR. Initiating PCSK9 inhibition in hospital for ACS: we can, but does that mean we should?. J Am Coll Cardiol. 2019, 74:2463-5. 10.1016\/j.jacc.2019.09.039","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suaa063","article-title":"Proprotein convertase subtilisin\/kexin type 9: an update on the cardiovascular outcome studies","volume":"22","author":"Ferri N","year":"2020","unstructured":"Ferri N, Grego MF, Corsini A, Ruscica M. Proprotein convertase subtilisin\/kexin type 9: an update on the cardiovascular outcome studies. Eur Heart J Suppl. 2020, 22:E64-7. 10.1093\/eurheartj\/suaa063","journal-title":"Eur Heart J Suppl"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.140","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives","volume":"35","author":"Cho KH","year":"2020","unstructured":"Cho KH, Hong YJ. Proprotein convertase subtilisin\/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives. Korean J Intern Med. 2020, 35:1045-58. 10.3904\/kjim.2020.140","journal-title":"Korean J Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2018.7.1.1","article-title":"How to interpret recent CV outcome trials and future: PCSK9 inhibitors","volume":"7","author":"Lee EY","year":"2018","unstructured":"Lee EY, Yoon KH. How to interpret recent CV outcome trials and future: PCSK9 inhibitors. J Lipid Atheroscler. 2018, 7:1-11. 10.12997\/jla.2018.7.1.1","journal-title":"J Lipid Atheroscler"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2019.00014","article-title":"Interpreting the findings from the recent PCSK9 monoclonal antibody cardiovascular outcomes trials","volume":"6","author":"Wong ND","year":"2019","unstructured":"Wong ND, Shapiro MD. Interpreting the findings from the recent PCSK9 monoclonal antibody cardiovascular outcomes trials. Front Cardiovasc Med. 2019, 6:14. 10.3389\/fcvm.2019.00014","journal-title":"Front Cardiovasc Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/2047487320941987","article-title":"Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial","volume":"28","author":"Diaz R","year":"2021","unstructured":"Diaz R, Li QH, Bhatt DL, et al.. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol. 2021, 28:33-43. 10.1177\/2047487320941987","journal-title":"Eur J Prev Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz GG","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al.. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018, 379:2097-107. 10.1056\/NEJMoa1801174","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021, 88:105906. 10.1016\/j.ijsu.2021.105906","journal-title":"Int J Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011748.pub2","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"4","author":"Schmidt AF","year":"2017","unstructured":"Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017, 4:CD011748. 10.1002\/14651858.CD011748.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320924569","article-title":"The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease","volume":"11","author":"Kim EJ","year":"2020","unstructured":"Kim EJ, Wierzbicki AS. The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. Ther Adv Chronic Dis. 2020, 11:10.1177\/2040622320924569","journal-title":"Ther Adv Chronic Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 inhibitors: mechanism of action, efficacy, and safety","volume":"19","author":"Roth EM","year":"2018","unstructured":"Roth EM, Davidson MH. PCSK9 inhibitors: mechanism of action, efficacy, and safety. Rev Cardiovasc Med. 2018, 19:S31-46. 10.3909\/ricm19S1S0002","journal-title":"Rev Cardiovasc Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049447","article-title":"Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol: a propensity score-matched analysis of the ODYSSEY OUTCOMES trial","volume":"143","author":"Schwartz GG","year":"2021","unstructured":"Schwartz GG, Gabriel Steg P, Bhatt DL, et al.. Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol: a propensity score-matched analysis of the ODYSSEY OUTCOMES trial. Circulation. 2021, 143:1109-22. 10.1161\/CIRCULATIONAHA.120.049447","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy301","article-title":"What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?","volume":"115","author":"Banach M","year":"2019","unstructured":"Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?. Cardiovasc Res. 2019, 115:e26-31. 10.1093\/cvr\/cvy301","journal-title":"Cardiovasc Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.10.138","article-title":"The effects of proprotein convertase subtilisin\/kexin type 9 inhibitors on lipid metabolism and cardiovascular function","volume":"109","author":"Amput P","year":"2019","unstructured":"Amput P, McSweeney C, Palee S, Phrommintikul A, Chattipakorn SC, Chattipakorn N. The effects of proprotein convertase subtilisin\/kexin type 9 inhibitors on lipid metabolism and cardiovascular function. Biomed Pharmacother. 2019, 109:1171-80. 10.1016\/j.biopha.2018.10.138","journal-title":"Biomed Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/10742484221100107","article-title":"A comprehensive review of PCSK9 inhibitors","volume":"27","author":"Coppinger C","year":"2022","unstructured":"Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M. A comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther. 2022, 27:10.1177\/10742484221100107","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3179201","article-title":"Cardiovascular outcomes of PCSK9 inhibitors: with special emphasis on its effect beyond LDL-cholesterol lowering","volume":"2018","author":"Bandyopadhyay D","year":"2018","unstructured":"Bandyopadhyay D, Ashish K, Hajra A, Qureshi A, Ghosh RK. Cardiovascular outcomes of PCSK9 inhibitors: with special emphasis on its effect beyond LDL-cholesterol lowering. J Lipids. 2018, 2018:3179201. 10.1155\/2018\/3179201","journal-title":"J Lipids"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.595819","article-title":"PCSK9 inhibition: insights from clinical trials and future prospects","volume":"11","author":"Katzmann JL","year":"2020","unstructured":"Katzmann JL, Gouni-Berthold I, Laufs U. PCSK9 inhibition: insights from clinical trials and future prospects. Front Physiol. 2020, 11:595819. 10.3389\/fphys.2020.595819","journal-title":"Front Physiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner VA","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, et al.. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020, 75:133-44. 10.1016\/j.jacc.2019.10.057","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson RS","year":"2018","unstructured":"Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018, 72:314-29. 10.1016\/j.jacc.2018.04.054","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca MP","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, et al.. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018, 137:338-50. 10.1161\/CIRCULATIONAHA.117.032235","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-020-00163-w","article-title":"What lessons have we learned and what remains to be clarified for PCSK9 inhibitors? A review of FOURIER and ODYSSEY Outcomes trials","volume":"9","author":"Furtado RH","year":"2020","unstructured":"Furtado RH, Giugliano RP. What lessons have we learned and what remains to be clarified for PCSK9 inhibitors? A review of FOURIER and ODYSSEY Outcomes trials. Cardiol Ther. 2020, 9:59-73. 10.1007\/s40119-020-00163-w","journal-title":"Cardiol Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5935\/abc.20190029","article-title":"PCSK9 inhibitors: clinical relevance, molecular mechanisms, and safety in clinical practice","volume":"112","author":"Ferrari F","year":"2019","unstructured":"Ferrari F, Stein R, Motta MT, Moriguchi EH. PCSK9 inhibitors: clinical relevance, molecular mechanisms, and safety in clinical practice. Arq Bras Cardiol. 2019, 112:453-60. 10.5935\/abc.20190029","journal-title":"Arq Bras Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038840","article-title":"Effect of alirocumab on mortality after acute coronary syndromes: an analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"140","author":"Steg PG","year":"2019","unstructured":"Steg PG, Szarek M, Bhatt DL, et al.. Effect of alirocumab on mortality after acute coronary syndromes: an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation. 2019, 140:103-12. 10.1161\/CIRCULATIONAHA.118.038840","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-020-00557-6","article-title":"Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials","volume":"19","author":"Cordero A","year":"2020","unstructured":"Cordero A, Rodr\u00edguez-Ma\u00f1ero M, F\u00e1cila L, et al.. Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials. J Diabetes Metab Disord. 2020, 19:759-65. 10.1007\/s40200-020-00557-6","journal-title":"J Diabetes Metab Disord"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/1753944718775352","article-title":"Alirocumab as add-on therapy to statins: current evidence and clinical potential","volume":"12","author":"Auer J","year":"2018","unstructured":"Auer J, Berent R. Alirocumab as add-on therapy to statins: current evidence and clinical potential. Ther Adv Cardiovasc Dis. 2018, 12:191-202. 10.1177\/1753944718775352","journal-title":"Ther Adv Cardiovasc Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/102678-reduction-of-cardiovascular-risk-using-proprotein-convertase-subtilisinkexin-type-9-inhibitors-in-patients-with-acute-coronary-syndrome-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:31Z","timestamp":1707508171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/102678-reduction-of-cardiovascular-risk-using-proprotein-convertase-subtilisinkexin-type-9-inhibitors-in-patients-with-acute-coronary-syndrome-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,5]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.34648","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,5]]}}}